Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and hepatitis C virus

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), interleukin‐6 (IL‐6), and IL‐17,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2022-05, Vol.94 (5), p.2296-2301
Main Authors: León, Fabiola Justina Fumero, Silva, Lucas Lima, Santos, Alanna Calheiros, Duarte da Costa, Vanessa, Miguel, Juliana Custódio, Marques, Julia Trece, Nascimento, Giselle Prado, Ferreira da Silva, Elisangela, Lewis‐Ximenez, Lia Laura, Villar, Livia Melo, Paula, Vanessa Salete
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
Cytokine Release Syndrome
Cytokine storm
Cytokines
Hepacivirus
Hepatitis
Hepatitis C
Humans
IL‐17
IL‐6
Immunoassay
Immunology
Inflammation
Inflammatory response
Interleukin 6
Liver
Liver diseases
Monitoring
Polymerase chain reaction
Respiratory diseases
SARS-CoV-2
Serology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Short Communication
Telemedicine
TNF‐α
Tumor necrosis factor
Tumor necrosis factor-TNF
Viral diseases
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), interleukin‐6 (IL‐6), and IL‐17, all of which can affect the liver. Here, we aimed to evaluate the cytokine profiles of patients suffering from coronavirus disease (COVID)‐19 and/or hepatitis. We subjected 87 patients to serology and/or polymerase chain reaction analysis for the hepatitis C virus. They were also tested for TNF‐α, IL‐6, and IL‐17 using commercial immunoassay kits. The test results of the COVID‐19/hepatitis C patients (n = 8) were compared with that of the negative controls (n = 28), hepatitis C patients (n = 29), and COVID‐19 patients (n = 22). All COVID‐19 patients (mono‐ and coinfected) expressed high levels of cytokines. The COVID‐19/hepatitis patients exhibited higher levels of IL‐6 (6.33 ± 3.9 pg/ml) and IL‐17 (102.23 ± 2.7 pg/ml); however, TNF‐α values were lower (68.08 ± 15.88 pg/ml), as compared with that of the hepatitis patients (p 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.27614